Russian company Infectex has announced the completion of clinical trials of SQ109, a world-unique drug to treat TB Biotechnology company Infectex (resident of the Skolkovo Foundation Biomed Cluster, a portfolio company of Maxwell Biotech Venture Fund) has...
Hepatera LLC, a biotechnology company of Maxwell Biotech Group and a resident of the Skolkovo Foundation Biomed Cluster, has completed the patient recruitment for phase 2b clinical trials of Myrcludex B innovative medical drug. Hepatera is implementing a...
Saint Petersburg, July 16, 2016 – The Russian Direct Investment Fund (RDIF) is delighted to announce that it has today signed an agreement at the St. Petersburg International Economic Forum, to launch a project to create a Russian Centre for medical robots...